StemCell Therapy

FDA approves Genentechs Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States.

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) approved Lucentis(ranibizumab injection) 0.3 mg for the monthly treatment of all forms of diabetic retinopathy. The most common cause of vision loss in people with diabetes, diabetic retinopathy is the leading cause of blindness among adults aged 20 to 741and affects nearly 7.7 million people in the U.S.2

With this approval, Lucentis becomes the first and only FDA-approved medicine to treat diabetic retinopathy in people who have been diagnosed either with or without diabetic macular edema (DME), a complication of diabetic retinopathy that causes swelling in the back of the eye. In February 2015, Lucentis received FDA approval for the treatment of diabetic retinopathy in people with DME based on data from the pivotal RIDE and RISE Phase III clinical trials.

The FDA granted Lucentis Priority Review for the treatment of diabetic retinopathy without DME based on an analysis of the Diabetic Retinopathy Clinical Research Networks (DRCR.net) Protocol S study. This NIH-funded study compared Lucentis treatment to panretinal laser treatment in diabetic retinopathy patients both with and without DME.

In the analysis that supported this approval, patients with and without DME in the Lucentis group experienced improvements in the severity of their retinopathy. Adverse events were consistent with those seen in previous studies.

Diabetic retinopathy is the leading cause of vision loss among working-aged adults in the U.S. between the ages of 20 and 74. We are very pleased that Lucentis is now FDA-approved to treat retinopathy in people with and without DME, said Sandra Horning, M.D., chief medical officer and head of Global Product Development. In multiple clinical studies, Lucentis demonstrated a significant improvement of patients diabetic retinopathy, and it is the first and only anti-VEGF therapy approved to treat all forms of diabetic retinopathy.

Priority Review Designation is granted to medicines that the FDA has determined to have the potential to provide significant improvements in the safety and effectiveness of the treatment of a serious disease.

The FDA previously granted Lucentis Breakthrough Therapy Designation for diabetic retinopathy in 2014 based on the pivotal RIDE and RISE phase III clinical trials. Breakthrough designation is intended to expedite the development and review of medicines with early evidence of potential clinical benefit in serious diseases and to help ensure that patients receive access to medicines as soon as possible.

Diabetes affects more than 29 million people in the U.S.3The longer a person has diabetes, especially if it is poorly controlled, the higher the risk of developing diabetic retinopathy and vision loss. Diabetic retinopathy occurs when blood vessels in the retina become damaged. This can cause vision loss or distortion when the abnormal vessels leak blood or fluid into the eye.1 ___________________________________________________

References:

1U.S. Centers for Disease Control and Prevention. Common Eye Disorders: Diabetic Retinopathy. Available athttps://www.cdc.gov/visionhealth/basics/ced/index.html. Accessed March 7, 2017.

2Prevent Blindness America. Diabetic Retinopathy. Available athttp://www.visionproblemsus.org/diabetic-retinopathy/diabetic-retinopathy-definition.html. Accessed March 7, 2017.

3American Diabetes Association. Statistics About Diabetes. Available athttp://www.diabetes.org/diabetes-basics/statistics/. Accessed March 7, 2017.

(Source: Business Wire)

Read the original here:
Genentech's Lucentis Approved for Blindness-Causing Diabetic Retinopathy - Pharmaceutical Processing

This entry was posted on April 18, 2017 at 7:44 pm and is filed under Blindness. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |